Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

AB218 gloma (Anheart) : A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting

Multiple<Br/>Treatment TypesTypeMultiple
Treatment Types

OnePhase One

18-40Age 18-40

Brain and Spinal<br/>CancersCancer LocationBrain and Spinal

Multiple treatment types,Surgical,Systemic therapy,Treatment | Brain and spinal cordGlioma

Trial Overview Read MoreRead more

This early phase I study is assessing the feasibility of treatment with targeted therapy (AB-218) prior to surgery in people with IDH1 mutated brain cancer (glioma).

This trial is treating patients with IDH1 mutated Low Grade Glioma.

This is a systemic therapy and surgical trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 0/2 Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

Other Non-Commercial Sponsor

Melbourne Health


Eligible participants will receive treatment in two parts. In Part A, participants will undergo a biopsy, followed by one cycle (28 days) of treatment with AB-218, an orally available, small molecule inhibitor of mutated IDH1, and then a safe maximal resection (surgery) of the tumour. In Part B, following recovery from surgery, participants will receive up to 12 cycles of AB-218.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Richelle Linklater

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.